Change of Adviser

18/08/2011

Oxford Pharmascience Group Plc

("Oxford Pharmascience" or "the Company")

Change of Adviser

Oxford Pharmascience Group Plc is pleased to announce the appointment of Hybridan LLP as broker to the Company with immediate effect. ZAI Corporate Finance remains Nominated Adviser to the Company.

The Directors accept responsibility for the content of this announcement.

For further information:

Oxford Pharmascience Group Plc

Nigel Theobald, Chief Executive +44 1865 854874

ZAI Corporate Finance (Nominated Adviser)

John Depasquale +44 20 7060 2220

Sarang Shah +44 20 7060 2220

Hybridan LLP (Broker)

Claire Noyce +44 20 7947 4350

About Oxford Pharmascience Group Plc

-- Oxford PharmaScience are specialists in the repositioning of medicines via reformulation using advanced pharmaceutic technologies to add value to generic and soon to be generic drugs;

-- Technology portfolio includes superior chewable tablets, liquid suspensions, and solid state suspensions (soft chews) as well as modified drug delivery technologies to achieve either taste masking or targeted release effects.

-- The company uses its technologies to develop Drug Master Files (DMF's) and full CTD dossiers (drug registration dossiers) for a range of medicines initially with focus on NSAIDs, statins and calcium.

-- Oxford Pharmascience works closely with leading academic institutions to further advance its intellectual property portfolio to apply to generic and soon to be generic drugs.

- Ends -